Regarding the pathophysiology and management of local anesthetic systemic toxicity (LAST), all of the following statements are correct EXCEPT:

Explanation

## Pathophysiology and Management of Local Anesthetic Systemic Toxicity (LAST) **Key Point:** LAST is a life-threatening complication of regional anesthesia requiring prompt recognition and treatment. The ASRA (American Society of Regional Anesthesia) guidelines provide the current evidence-based framework for management. ### Evaluating Each Statement **Option A — CORRECT:** Lipid emulsion therapy works via the "lipid sink" mechanism. The infused lipid creates a separate pharmacokinetic compartment that sequesters lipophilic local anesthetic molecules (especially bupivacaine) away from cardiac and CNS tissues, reducing the free drug concentration at target organs. This is well-established in Miller's Anesthesia and ASRA guidelines. **Option B — CORRECT:** Bupivacaine's greater cardiotoxicity compared to lidocaine is explained by its slow dissociation kinetics from cardiac sodium channels ("fast-in, slow-out"). Lidocaine follows "fast-in, fast-out" kinetics, allowing channel recovery between action potentials. Bupivacaine's prolonged channel blockade leads to refractory ventricular fibrillation and cardiac arrest that is resistant to standard ACLS. *(Miller's Anesthesia, 8th ed., Ch. 16)* **Option C — CORRECT:** While the classic teaching describes an excitatory phase (circumoral numbness, tinnitus, tremors, seizures) followed by CNS depression, this progression is **not invariable**. In patients under sedation or general anesthesia, the excitatory phase may be completely masked, and the patient may present directly with CNS depression (unconsciousness, apnea). Therefore, the word "always" makes this statement false — but it is the **EXCEPT** answer only if it is the most clearly incorrect statement. **Option D — INCORRECT (the EXCEPT answer):** Current ASRA LAST guidelines (2020) do **NOT** state that vasopressors should be avoided entirely. Rather: - **Standard high-dose epinephrine (≥1 mcg/kg) should be avoided** as it worsens arrhythmias and impairs lipid resuscitation efficacy - **Reduced-dose epinephrine (≤1 mcg/kg)** is acceptable and may be necessary in refractory cardiac arrest - **Vasopressin is also not recommended** per ASRA 2020 guidelines - Lipid emulsion is the **primary** treatment, but vasopressors are not categorically contraindicated The blanket statement that "vasopressors should be avoided" is factually incorrect per current guidelines — this makes Option D the most clearly wrong statement. **Clinical Pearl:** The ASRA 2020 LAST checklist explicitly states: "Avoid vasopressin; if vasopressors are needed, use epinephrine at doses ≤1 mcg/kg." Vasopressors are not absolutely contraindicated — only high doses and vasopressin are discouraged. ### LAST Management Summary | Intervention | Recommendation | |---|---| | **Lipid emulsion 20%** | 1.5 mL/kg bolus → 0.25 mL/kg/min infusion (first-line) | | **Epinephrine** | Reduced dose ≤1 mcg/kg if needed; avoid standard ACLS doses | | **Vasopressin** | Avoid (ASRA 2020) | | **Amiodarone** | Preferred antiarrhythmic over lidocaine | | **ECMO/CPB** | Consider for refractory arrest | | **Benzodiazepines** | Seizure control | **High-Yield:** Option D's absolute claim that vasopressors "should be avoided" contradicts ASRA guidelines, which permit reduced-dose epinephrine. Option C, while containing the word "always," reflects a well-known teaching point about LAST presentations under sedation — but Option D contains a more definitive factual error regarding current management guidelines. [cite: ASRA LAST Guidelines 2020; Miller's Anesthesia 8th ed., Ch. 16]